TargImmune successfully closed its 2021 financing round


TargImmune successfully closed its 2021 financing round and appoints Peter Braun as Chief Executive Officer

TargImmune successfully closed its 2021 financing round and appoints Peter Braun as Chief Executive Officer

Basel, Switzerland, July 9, 2021

TargImmune Therapeutics AG (Basel, Switzerland), a privately held Swiss-based biotechnology company focused on the development of new medicines through the use of novel targeted immunotherapies, today announced that Peter Braun, who has extensive experience in the healthcare industry and most recently led the biopharmaceutical company Nordic Nanovector, has been appointed Chief Executive Officer (CEO), effective August 16, 2021. He will succeed Esteban Pombo-Villar, who has built the company over the past four years and will now focus on leading key projects in chemistry and biology as Chief Technology Officer (CTO).

TargImmune has just successfully closed its 2021 financing round, raising CHF 17.7 million. This expands the company’s cash position into the clinical development of its lead candidate Tar001. With significant progress in the development of TargImmune’s unique RNA drug platform, the company has all the tools and processes in place to file an Investigational New Drug Application (IND) with the FDA and start the clinical program in the second quarter of next year. The company is on track to complete regulatory toxicology studies (GLP) as planned later this year.

“I am very pleased that we are appointing Peter Braun as TargImmune’s new CEO, who has broad and international experience in the healthcare industry and a deep understanding of our business and the oncology space. He has a strong track record of leadership, strategy and execution. We are convinced that he is exactly the right person to lead TargImmune’s next important development steps”, says Kuno Sommer, Chairman of the Board of Directors of TargImmune. “I would also like to thank Esteban Pombo-Villar for his leadership, dedication and great work over the last years. Esteban has successfully built TargImmune from a university spin-off to a company preparing for clinical development of its drug candidates. He has a deep understanding of the chemistry and biology of our assets and as CTO will focus on developing our unique technology platform. Together with Peter and Esteban, TargImmune has a strong and very complementary leadership team that will take the company to the next level."

Peter Braun is an accomplished, entrepreneurial, commercially and strategically astute leader with more than 25 years of experience in building businesses and delivering strong, sustainable results across the pharmaceutical and healthcare value chain. Previously, he held leadership positions in the biotechnology and biopharmaceutical industry and served as a strategic advisor to several emerging companies. Prior to that, Peter Braun had a long and successful career at Roche with senior leadership roles such as Lifecycle Leader for Herceptin, Country Head and most recently as Global Head of Access Strategy. He holds a BSc in Economics from Wharton School of Business and a BA in Int'l Relations from the College of Arts and Sciences from the University of Pennsylvania (US) and an MBA from INSEAD, France.

Dr. Esteban Pombo-Villar has over 30 years of experience in biopharmaceutical R&D and business development leadership. Prior to joining TargImmune, he was Chief Operations Officer (COO) at Oxford BioTherapeutics. Prior to that, Dr. Pombo-Villar spent over 23 years at Novartis and Sandoz, the last 12 years in Business Development and Alliance Management and as Head of Alliance Management at the Novartis Institute for Biomedical Research (NIBR). Dr. Pombo-Villar earned a PhD, MSc and BSc in organic chemistry from the University of Warwick (UK) and was a visiting researcher at the University of Newcastle upon Tyne (UK). He then completed postdoctoral studies at the ETH in Zurich. He is a Fellow of the Royal Society of Chemistry, a member of several scientific societies, and has completed executive business studies at IMD (MTE, Lausanne), Harvard Business School (US), and the Tuck School of Business (Dartmouth, US).

For further information please contact:
For Investors:
Christoph Rentsch
Chief Financial Officerr
TargImmune Therapeutics AG
+41 79 221 99 34

For Media:
Dr. Stephan Feldhaus
Feldhaus & Partner
+41 79 865 92 56

About TargImmune
TargImmune Therapeutics AG, a private Swiss-based biotechnology firm focused on drug development using novel targeted immunotherapies. The Company's principal technology is the CTPIC technology platform that utilizes a proprietary non-viral vector to target and destroy cancer cells that overexpress certain receptors. TargImmune is the only targeted immunotherapy company that leverages three simultaneous mechanisms of action. Tumors thrive because they escape from the immune system. Targimmune’s drugs specifically target the tumors, initiating cell death, forcing the cancers to attract the immune system to complete the attack and destruction of the tumors, also destroying neighboring cancer cells in heterogeneous tumors. The drugs are delivered by systemic injection, so they reach distant metastasis, which are the leading cause of cancer death. These innovative properties result in excellent in vivo activity even as single drugs. TargImmune Therapeutics is based in Basel. For more information, please visit

This press release contains forward-looking statements which are based on current assumptions and forecasts of the TargImmune management. Known and unknown risks, uncertainties, and other factors could lead to material differences between the forward-looking statements made here and the actual development, in particular TargImmune’s results, financial situation, and performance. Readers are cautioned not to put undue reliance on forward-looking statements, which speak only of the date of this communication. TargImmune disclaims any intention or obligation to update and revise any forward-looking statements, whether as a result of new information, future events or otherwise.

Source: Press Release

Go back